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SHORT COMMUNICATION
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Summary We have observed that low pH can substantially potentiate the cytotoxic effect of the bioreductive
drug SR4233 in aerobic HT-29 human tumour cells. No such potentiation was observed under hypoxic
conditions. This pH effect might be relevant both to the therapeutic effectiveness and to the normal tissue
toxicity of this new agent.
The bioreductive drug 1,2,4-Benzotriazin-3-amine 1,4-Di-
oxide (SR4233 or WIN59075) has been shown to have a
remarkably selective toxicity for hypoxic cells (Zeman et al.,
1986), a property which has stimulated much interest in its
potential as an adjunct to radiation and chemotherapy. It is
believed that the active form of the agent is an oxygen-
sensitive, 1-electron reduction product (Laderoute et al.,
1988; Baker et al., 1988). A potentially important secondary
property of SR4233 is its reported ability to act as a radio-
sensitiser of aerobic cells which receive a pre- or post-
irradiation exposure to the drug under hypoxic conditions
(Zeman & Brown, 1989). These authors suggested that this
characteristic might be effective in dealing with the problem
of transient hypoxia known to occur in experimental tumours
(Chaplin et al., 1986, 1987). It has also been shown that
hydralazine can potentiate the cytotoxic effect of SR4233 in a
mouse tumour system (Brown, 1987).
While there has been extensive study of the effect of hypoxia
on the cytotoxicity of SR4233, there has been relatively little
attention given to the influence of other microenvironmental
factors which might be important to the anti-tumour poten-
tial of this drug (Tocher et al., 1990; Herman et al., 1990). In
this paper we describe the influence of pH on the cytotoxic
effect of SR4233 under both aerobic and hypoxic conditions.
Materials and methods
The cytotoxicity of SR4233 was examined in human colon
adenocarcinoma HT-29 cells (from American Type Culture
Collection, Rockville, Maryland, USA). These cells were
grown as monolayer cultures in McCoy's SA medium, supple-
mented with 10% foetal bovine serum (both from Gibco,
Burlington, Ontario, Canada), penicillin (80 units ml-') and
streptomycin (80 lg ml-') and sodium bicarbonate (2.2 g 1'-).
Monolayers were sub-cultured using a 0.25% trypsin solu-
tion. For experiments, cell suspensions were prepared at
2 x I05 cells ml-' in normal growth medium lacking sodium
bicarbonate but supplemented with 20 mM BIS-TRIS (bis[2-
Hydroxyethyl]imino-tris-hydroxymethyl] methane, from Sigma
Chemical Co., St. Louis, MO, USA) for control of pH. Cell
suspensions were prepared at each pH to be investigated,
ranging from 6.0 to 7.4, using pH-adjusted medium. Nine ml
of cell suspension were then placed in each 24 wide-mouth,
50 ml Erlenmeyer flasks. The vessels were fitted with stoppers
which provided ports for gas in, gas out, and sampling. The
flasks were placed in a 37°C rotary shaker bath and each
flask was gassed with humidified air or N2 (141min-') in a
37°C warm room. Following 45 min gassing, SR4233 aliquots
were added to yield the prescribed experimental concentra-
tion. Controls and a single drug concentration (1000 LM for
the aerobic and 40 ^.M for the hypoxic treatment) were used.
After 60 min incubation time, aliquots were removed from
each flask, spun down and washed twice to remove the drug.
Appropriate inocula were plated in 60 mm petri dishes for
colony formation measurement. The pH of the cell suspen-
sions was checked at the end of the 60 min incubation
period. Although the pH generally decreased during this
period, the changes were small: suspensions with a nominal
pH of 6.60, for example, were found to have final pH's of
6.52 to 6.60 at the end of the incubation period.
Drug preparation
SR4233 was kindly provided by Dr M. Tracy of Stanford
Research Institute, Menlo Park, CA, USA. Approximately
45 min before the SR4233 treatment was to begin, a fresh
stock solution of SR4233 was prepared by dissolving the
drug in 37°C medium (buffered by BIS-TRIS) for 10 min,
followed by sonication at 37°C for 5 min. The concentration
of SR4233 was 10 mM (solubility limit is 13.5 mM). The stock
solution was sterile-filtered and diluted to provide appro-
priate concentrations.
Results
Figure 1 shows the effect of pH on the cytotoxicity of
SR4233 in HT-29 human colon adenocarcinoma cells, for
both aerobic and hypoxic conditions. The cells were incu-
bated at 37°C for 1 h in complete medium containing
1000 LM or 40 tlM SR4233 for aerobic or hypoxic conditions,
respectively. These conditions were chosen to yield approx-
imately equivalent cell kill at pH 6.6 and they illustrate the
striking potentiation of SR4233 cytotoxicity that occurs with
hypoxic conditions. It can be seen that the plating efficiency
of these cells, in the absence of drug, is unaffected by pH and
is approximately the same under both aerobic and hypoxic
conditions (range 50-86%). Under aerobic conditions, the
cytotoxic effect of 1000 JSM SR4233 is strongly potentiated by
low pH; the cell kill at pH 6.0 is approximately 300-fold
greater than at pH 7.4. Under hypoxic treatment, however,
low pH seems to have, if anything, a slightly protective effect
against SR4233 cytotoxicity.
Discussion
Our studies with HT-29 human tumour cells have shown that
the cytotoxic effect of SR4233 is greatly enhanced under
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Figure 1 Effect of pH on the cytotoxicity of SR4233 in HT-29
human colon adenocarcinoma cells. Exposure for 1 h at 37°C and
the indicated pH to SR4233 under aerobic conditions (open
circles, [SR4233]= 1000 SAM) or hypoxic conditions (closed
circles, [SR4233] = 40 gM). The results are pooled from three
different experiments.
hypoxic conditions, consistent with the results of Zeman et
al. (1986) in several different rodent and human cell lines.
The potentiation of the aerobic cytotoxicity of SR4233 which
we found associated with low extracellular pH, has not been
previously described, to our knowledge. Tocher et al. (1990)
reported that acidic pH led to increased activity of reduced
SR4233 in a p x 174 DNA damage assay under hypoxia but
no aerobic results were given. Herman et al. (1990) reported
that low pH (6.45) enhanced the hypoxic cytotoxicity of
SR4233 against a mouse tumour cell line, FSaIIC, by approxi-
mately 2-fold, but had no effect on the aerobic response;
results with that cell line were unusual, however, in that
hypoxia only enhance the cytotoxicity of SR4233 by a factor
of 2 to 3.
If the acidic potentiation of the aerobic cytotoxicity of
SR4233 reported here is found to be a general property of
the drug (we have recently observed it as well in SiHa cells, a
human cervical squamous carcinoma cell line), it adds an
interesting third dimension to the potential therapeutic value
of this drug, in addition to the hypoxic cytotoxicity and the
aerobic radiosensitisation (Zeman et al., 1986; Zeman &
Brown, 1989). The reported aerobic radiosensitization has
been identified as a potentially useful property of the drug in
treating tumours where intermittent blood flow and its conse-
quent transient hypoxia may compromise the hypoxic cyto-
toxicity of SR4233. The effect was credited with producing a
significant therapeutic gain in fractionated irradiation of
mouse tumours (Brown & Lemmon, 1991). Since low pH and
hypoxia are conditions which will often coexist in certain
tumour cell subpopulations and since acidic conditions are
probably less variable and longer-persisting than (intermit-
tent) hypoxia in solid tumours, the low pH potentiation of
SR4233 cytotoxicity described here could also play a role in
contributing to therapeutic gain.
It is also possible that the potentiation of SR4233 toxicity
by acidic pH under aerobic conditions could contribute to
the potentiation observed when SR4233 is combined with
agents which induce ischemia (Sun & Brown, 1989; Edwards
et al., 1991; Braunschweiger et al., 1991). It would be
expected that agents such as FAA and TNF, which induce
permanent vascular occlusion in a large proportion of
tumour vessels, would result in a significant acidification of
the tumour micromilieu. Indeed, since acidic metabolites will
diffuse throughout the tumour mass until removed via the
vascular system, significant pH reduction around and close to
functioning vessels might be expected. Based on our results
reported here, such an acidification would make these aerobic
cells more susceptible to killing by SR4233.
We have not addressed the mechanism responsible for the
preferential effect of acidic conditions on the aerobic cytotox-
icity of SR4233. However, it has been suggested that the
toxicity of SR4233 under aerobic conditions is due to
the production of damaging oxygen species derived from the
back oxidation of the one-electron reduction product (Lader-
oute et al., 1988; Baker et al., 1988). If this is true, acidic pH
could increase aerobic toxicity by decreasing the removal or
increasing the production of damaging oxygen species. What-
ever the exact mechanism responsible, if the limiting normal
tissue toxicity observed when clinical trials are initiated is
related to the aerobic toxicity in vitro, tissue pH could play a
role in determining the severity of toxicity.
In summary, the in vitro results demonstrate that the
aerobic toxicity of SR4233 is enhanced under conditions of
acidic pH. In contrast, no enhancement of the hypoxic tox-
icity of SR4233 by acidic pH could be demonstrated. This
finding may indicate that pH could play a role in both the
tumour cytotoxicity and normal tissue damage.
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